Pfizer Inc (PFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pfizer Inc (PFE) has a cash flow conversion efficiency ratio of 0.029x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.62 Billion) by net assets ($90.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of Pfizer Inc to assess the company's strategic physical and investment asset allocation.
Pfizer Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See PFE net asset value for net asset value and shareholders' equity analysis.
Pfizer Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Welltower Inc
NYSE:WELL
|
0.015x |
|
Honeywell International Inc
NASDAQ:HON
|
0.076x |
|
Pfizer Inc
SA:PFIZ34
|
0.029x |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
0.052x |
|
Uber Technologies Inc
NYSE:UBER
|
0.103x |
|
Schneider Electric S.E.
PA:SU
|
0.202x |
|
Deere & Company
NYSE:DE
|
-0.034x |
|
ALLIANZ SE UNSP.ADR 1/10
F:ALVE
|
N/A |
Annual Cash Flow Conversion Efficiency for Pfizer Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see PFE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.78 Billion | $11.71 Billion | 0.135x | -6.33% |
| 2024-12-31 | $88.50 Billion | $12.74 Billion | 0.144x | +47.79% |
| 2023-12-31 | $89.29 Billion | $8.70 Billion | 0.097x | -68.07% |
| 2022-12-31 | $95.92 Billion | $29.27 Billion | 0.305x | -27.45% |
| 2021-12-31 | $77.46 Billion | $32.58 Billion | 0.421x | +85.35% |
| 2020-12-31 | $63.47 Billion | $14.40 Billion | 0.227x | +14.37% |
| 2019-12-31 | $63.45 Billion | $12.59 Billion | 0.198x | -20.07% |
| 2018-12-31 | $63.76 Billion | $15.83 Billion | 0.248x | +8.00% |
| 2017-12-31 | $71.66 Billion | $16.47 Billion | 0.230x | -13.50% |
| 2016-12-31 | $59.84 Billion | $15.90 Billion | 0.266x | +19.02% |
| 2015-12-31 | $65.00 Billion | $14.51 Billion | 0.223x | -5.28% |
| 2014-12-31 | $71.62 Billion | $16.88 Billion | 0.236x | +1.67% |
| 2013-12-31 | $76.62 Billion | $17.77 Billion | 0.232x | +11.05% |
| 2012-12-31 | $81.68 Billion | $17.05 Billion | 0.209x | -14.77% |
| 2011-12-31 | $82.62 Billion | $20.24 Billion | 0.245x | +88.78% |
| 2010-12-31 | $88.27 Billion | $11.45 Billion | 0.130x | -29.24% |
| 2009-12-31 | $90.45 Billion | $16.59 Billion | 0.183x | -41.94% |
| 2008-12-31 | $57.74 Billion | $18.24 Billion | 0.316x | +54.05% |
| 2007-12-31 | $65.12 Billion | $13.35 Billion | 0.205x | -17.58% |
| 2006-12-31 | $70.72 Billion | $17.59 Billion | 0.249x | +12.05% |
| 2005-12-31 | $66.36 Billion | $14.73 Billion | 0.222x | -6.40% |
| 2004-12-31 | $68.88 Billion | $16.34 Billion | 0.237x | +32.11% |
| 2003-12-31 | $65.38 Billion | $11.74 Billion | 0.180x | -64.82% |
| 2002-12-31 | $19.95 Billion | $10.18 Billion | 0.510x | +0.80% |
| 2001-12-31 | $18.29 Billion | $9.26 Billion | 0.506x | +31.40% |
| 2000-12-31 | $16.08 Billion | $6.20 Billion | 0.385x | -60.25% |
| 1999-12-31 | $3.15 Billion | $3.06 Billion | 0.970x | +191.62% |
| 1998-12-31 | $8.81 Billion | $2.93 Billion | 0.332x | +68.95% |
| 1997-12-31 | $8.28 Billion | $1.63 Billion | 0.197x | -33.32% |
| 1996-12-31 | $7.00 Billion | $2.07 Billion | 0.295x | -10.02% |
| 1995-12-31 | $5.55 Billion | $1.82 Billion | 0.328x | -3.87% |
| 1994-12-31 | $4.36 Billion | $1.49 Billion | 0.341x | +5.48% |
| 1993-12-31 | $3.90 Billion | $1.26 Billion | 0.323x | +90.52% |
| 1992-12-31 | $4.75 Billion | $807.00 Million | 0.170x | +1.36% |
| 1991-12-31 | $5.06 Billion | $847.60 Million | 0.167x | -0.33% |
| 1990-12-31 | $5.12 Billion | $860.50 Million | 0.168x | +16.84% |
| 1989-12-31 | $4.56 Billion | $655.80 Million | 0.144x | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more